Medco Following Through On Companion Dx To Limit Drug Use
This article was originally published in The Gray Sheet
Executive Summary
The pharmacy benefit manager has prior authorization requirements for two expensive targeted oncology drugs, Xalkori and Zelboraf.
You may also be interested in...
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”